
Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC
Adagrasib (Krazati) plus pembrolizumab (Keytruda) improved efficacy for patients with KRAS G12C-mutated non–small cell lung cancer (NSCLC), according to results from the phase 2 KRYSTAL-7 trial (NCT04613596) presented at the 2025 American Society of …